AMIP, the Moroccan Pharmaceutical Industry Association, joins IGBA (September 2024)

IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that AMIP has been accepted and welcomed as a new IGBA Associate Member.

IGBA identifies streamlined development through reduced comparative clinical studies and appropriate use of global comparator product as key to greater biosimilar access (July 2024)

The mandate to conduct routine comparative clinical efficacy studies for biosimilar medicines, compounded by duplicative regional requirements, serves as a barrier to greater medicine access for patients. The International Generic and Biosimilar Medicines Association (IGBA) has issued two position papers; the first proposing streamlined development through reduced clinical studies and the second proposing use of the same comparator product across jurisdictions. 

IGBA Statement at the Opening of the Sessions at the WIPO Assemblies (July 2024)

Pharmaceutical innovation drives progress, and deserves reward, with intellectual property playing a key role in its protection. Expanding access to these innovations after rewarding them is crucial for public health. In well-functioning markets, generic and biosimilar medicines provide affordable, quality-assured therapeutic options enabling widespread access without compromising safety, efficacy, or quality. This balance supports Universal Health Coverage, reduces financial vulnerability, and ensures sustainable healthcare systems, contributing to Sustainable Development Goals 1, 3, and 10.

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

C/O DYN SA
Rue de Cornavin 11
1201 Geneva, Switzerland

E-mail: 
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Follow us on: LinkedIn - YouTube